Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.
Campus
Campus

Aubagio vs Ofatumumab

Aubagio® - strong in protecting the brain volume

Patients on AUBAGIO® had brain volume loss at 12 and 24 months comparable to patients on Ofatumumab. *,1

** The p-value was calculated at months 12-24 in both studies and the difference was not statistically significant.

Reference

  1. Hauser SL et al., N Engl J Med 2020;383(6)(Suppl 1):546-557. 

MAT-BH-2100790-Oct21